Parkinsonism associated with intraventricular amphotericin B.
Little information is available regarding the in-vivo effects of amphotericin B on organs other than the kidney. The increasing use of intrathecal amphotericin B has resulted in several reports of neurotoxicity associated with the drug. Development of parkinsonism following intraventricular treatment with amphotericin B for cryptococcal meningitis in a young woman suggested a direct toxic effect on nervous tissue by amphotericin B. Although transient signs of parkinsonism have been described in a patient receiving intraventricular amphotericin B, persistent parkinsonism is an unprecedented occurrence.
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003453:Cryptococcosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D008581:Meningitis / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*
D000666:Amphotericin B